Saturday, 05/07/2008

Skip navigation

Glossary | Site Map | Text Size: S L |
You are here: Home : Site Map

Site Map

Level 1 Item Home
Level 2 Item Company Profile
Level 3 Item Business Strategy
Level 3 Item People
Level 4 Item Scientific Advisory Board
Level 3 Item Awards
Level 3 Item MedImmune Cambridge And The Community
Level 4 Item Employment - Policies, Training And Benefits
Level 2 Item Careers @ Cambridge
Level 3 Item Why Join Us?
Level 3 Item Working Here
Level 4 Item Company Structure
Level 4 Item Our Vision and Values
Level 4 Item Living In The Cambridge Area
Level 3 Item Benefits And Rewards
Level 3 Item Application Tips
Level 3 Item Opportunities
Level 2 Item Products
Level 3 Item Product Pipeline
Level 4 Item Antibody Therapeutics
Level 4 Item Product Pipeline Chart
Level 3 Item Cambridge-derived Products
Level 4 Item CAT-8015
Level 4 Item CAT-354
Level 5 Item Severe Asthma
Level 4 Item GC-1008
Level 5 Item Idiopathic Pulmonary Fibrosis
Level 4 Item CAM-3001
Level 3 Item Licensed Products
Level 4 Item Abbott
Level 5 Item HUMIRA®
Level 5 Item ABT-874
Level 4 Item HGSI
Level 5 Item LymphoStat-B™
Level 5 Item HGS-ETR1
Level 5 Item HGS-ETR2
Level 5 Item ABthrax™
Level 6 Item Anthrax
Level 4 Item Wyeth
Level 5 Item MYO-029
Level 4 Item iCo
Level 5 Item CAT-213
Level 4 Item Dyax/ImClone
Level 4 Item Micromet
Level 3 Item MEDI-528
Level 2 Item Business Development
Level 3 Item Collaborative Alliances
Level 4 Item Genzyme
Level 4 Item CAT's Partnerships 1990-2002
Level 5 Item Abbott Laboratories
Level 6 Item Abbott Litigation
Level 5 Item Amgen
Level 5 Item Human Genome Sciences Inc
Level 5 Item Merk And Co
Level 5 Item Pfizer (pharmacia)
Level 5 Item Wyeth Research
Level 3 Item Our Partners
Level 4 Item Abbott Laboratories
Level 5 Item Abbott Litigation
Level 4 Item Affimed Tx
Level 4 Item Amgen Inc
Level 4 Item AstraZeneca
Level 4 Item BioInvent
Level 4 Item Chugai Pharmaceutical Co
Level 4 Item Crucell
Level 4 Item Dyax
Level 4 Item Enzon
Level 4 Item Genzyme
Level 4 Item Human Genome Sciences Inc
Level 4 Item iCo Therapeutics
Level 4 Item Merck And Co Inc
Level 4 Item Micromet
Level 4 Item Morphosys
Level 4 Item NovImmune SA
Level 4 Item Pfizer Inc
Level 4 Item Symphogen
Level 4 Item Wyeth Research
Level 4 Item Xoma Ltd
Level 4 Item Zenyth Therapeutics
Level 2 Item Drug Development
Level 3 Item Antibodies
Level 4 Item Background
Level 3 Item Core Technologies
Level 4 Item Antibody Libraries
Level 4 Item Phage Display
Level 4 Item Ribosome Display
Level 4 Item VelocImmune® Technology
Level 4 Item Isolating A Human Antibody
Level 3 Item Technology - IP
Level 4 Item Patent Licensing
Level 5 Item Affimed Therapeutics
Level 5 Item BioInvent
Level 5 Item Crucell
Level 5 Item Dyax
Level 5 Item Enzon
Level 5 Item Micromet
Level 5 Item Morphosys
Level 5 Item Symphogen
Level 5 Item Xoma
Level 4 Item Patents on CAT’s Technology
Level 3 Item Research Capabilities
Level 3 Item Development Capabilities
Level 3 Item Vaccines
Level 2 Item News And Resources
Level 3 Item News Archive
Level 4 Item 2007
Level 5 Item Cambridge Antibody Technology Licenses Monoclonal Antibody (CAT-213) For Treatment Of Allergy Disorders To iCo Therapeutics
Level 5 Item Cambridge Antibody Technology Reports That Astrazeneca Licenses Regeneron’s Velocimmune® Technology For Discovering Human Monoclonal Antibodies
Level 5 Item Cambridge Antibody Technology Names Its New Building In Honour Of Professor Sir Aaron Klug
Level 5 Item Cambridge Antibody Technology And Philochem Announce Technology Evaluation Agreement
Level 5 Item Astrazeneca Bolsters Its Worldwide Biologics Division Through Integration Of Cambridge Antibody Technology Into Medimmune
Level 4 Item 2006
Level 5 Item Cambridge Antibody Technology Announces Senior Management Promotions
Level 5 Item Macmillan Cancer Support To Benefit From Cambridge Antibody Technology Donation
Level 5 Item Cambridge Antibody Technology To Expand Operations In Cambridge, UK
Level 5 Item Arthur Rank Hospice To Benefit From Cambridge Antibody Technology Donation
Level 5 Item CAT And MSM Protein Technologies Enter Drug Discovery Collaboration In The Field Of Multi-Spanning Membrane Proteins
Level 5 Item Cambridge Antibody Technology And Debiopharm Enter Into An Exclusive Agreement To Develop And Market SC-1 For Gastric Cancer
Level 5 Item Cambridge Antibody Technology Announces Senior Management Appointment
Level 5 Item Cambridge Antibody Technology Announces Acquisition Of Oncology Product Candidate From Enzon
Level 5 Item Molecular Partners And CAT Sign Cross-licence Agreement In The Fields Of Repeat Protein Technology And Ribosome Display
Level 5 Item Scil Proteins And CAT Sign Cross-licence Agreement In The Field Of Affilin Technology And Ribosome Display
Level 5 Item Cambridge Antibody Technology Group plc Announces Resignation of Directors
Level 5 Item Cambridge Antibody Technology Appoints New Chief Executive
Level 5 Item Cambridge Antibody Technology Group plc Announces Interim Results for the Six Months Ended 31 March 2006
Level 5 Item Cambridge Antibody Technology Group plc Files Form 20-F
Level 5 Item Cambridge Antibody Technology Group plc Announces First Quarter Financial Results
Level 5 Item Cambridge Antibody Technology Group plc Reports Outcome of 2006 Annual General Meeting
Level 5 Item Cambridge Antibody Technology Group plc: Statement Re: Q1 2006 Financial Statement
Level 5 Item Cambridge Antibody Technology Reports HUMIRA® Sales Exceed $1 Billion In Annual Sales
Level 5 Item Cambridge Antibody Technology Announces Senior Management Appointment
Level 4 Item 2005
Level 5 Item Cambridge Antibody Technology Legal Action with Abbott: Ruling on Procedural Matters, 28 January 2005
Level 5 Item Cambridge Antibody Technology Announces Preliminary Results For The Year Ended 30 September 2005
Level 5 Item Cambridge Antibody Technology Legal Action with Abbott: Update RE Timing of Appeal
Level 5 Item Cambridge Antibody Technology Announces Senior Management Promotion
Level 5 Item Cambridge Antibody Technology Reports Recent Progress In Licensed Product Candidates
Level 5 Item Cambridge Antibody Technology Announces Senior Management Promotions
Level 5 Item Cambridge Antibody Technology Announces Data From Phase I Clinical Trial of CAT-354
Level 5 Item Cambridge Antibody Technology Legal Action with Abbott: Abbott Granted Permission to Appeal
Level 5 Item Cambridge Antibody Technology Announces Changes to the Board and Executive Group
Level 5 Item Cambridge Antibody Technology Group Plc Announces First Quarter Results
Level 5 Item Cambridge Antibody Technology Announces Financial Results for the Nine Months Ended 30 June 2005
Level 5 Item Cambridge Antibody Technology Legal Action with Abbott: Procedural Hearing on 28 January 2005
Level 5 Item Cambridge Antibody Technology Acquires Oncology Product Candidates From Genencor
Level 5 Item Cambridge Antibody Technology Announces Preliminary Results of Second Pivotal Trabio® Clinical Trial
Level 5 Item Cambridge Antibody Technology Legal Action with Abbott: Abbott Application for Permission to Appeal
Level 5 Item Cambridge Antibody Technology And Abbott Agree Regarding Royalties
Level 5 Item Cambridge Antibody Technology Appoints John Brown as Non-Executive Director
Level 5 Item Cambridge Antibody Technology Group Plc Reports Outcome of 2005 Annual General Meeting
Level 5 Item Cambridge Antibody Technology Announces Interim Results for the Six Months Ended 31 March 2005
Level 4 Item 2004
Level 5 Item Cambridge Antibody Technology Group Plc Interim Statement for the Six Months Ended 31 March 2004
Level 5 Item Cambridge Antibody Technology Group Plc Announces First Quarter Results
Level 5 Item Cambridge Antibody Technology and Genzyme Announce Preliminary Results from Phase I/II Trial of CAT-192 for Scleroderma
Level 5 Item Cambridge Antibody Technology Announces Financial Results for the Nine Months Ended 30 June 2004
Level 5 Item Cambridge Antibody Technology Prevails in Proceedings in High Court Re: Humira
Level 5 Item Cambridge Antibody Technology Legal Action with Abbott
Level 5 Item Cambridge Antibody Technology and AstraZeneca Announce Major Strategic Alliance
Level 5 Item Cambridge Antibody Technology: Clinical Trials Update
Level 5 Item Cambridge Antibody Technology Announces Preliminary Results of Trabio® Phase II/III Clinical Trial
Level 5 Item New Drug Candidate for Severe Asthma from Cambridge Antibody Technology Starts Clinical Trials
Level 5 Item Cambridge Antibody Technology Announces Senior Management Appointments and Promotion
Level 5 Item Cambridge Antibody Technology Group plc Announces Result of EGM
Level 5 Item Cambridge Antibody Technology Group Plc 2004 Annual General Meeting Statement
Level 5 Item Cambridge Antibody Technology and Lonza Extend Manufacturing Agreement
Level 5 Item Cambridge Antibody Technology Announces Preliminary Results for the Year Ended 30 September 2004
Level 5 Item Cambridge Antibody Technology Legal Action With Abbott: Judgement to be Announced on 20 December 2004
Level 5 Item Cambridge Antibody Technology Grants Licence to Wyeth
Level 5 Item Cambridge Antibody Technology Group Plc Reports Outcome of 2004 Annual General Meeting
Level 4 Item 2003
Level 5 Item Cambridge Antibody Technology Group PLC ("CAT") and Oxford Glycosciences PLCS ("OGS")
Level 5 Item Cambridge Antibody Technology Group plc Announces Financial Results for the Nine Months Ended 30 June 2003
Level 5 Item Cambridge Antibody Technology Receives First Payment of HUMIRA® Royalties From Abbott Laboratories
Level 5 Item Cambridge Antibody Technology Reports the Initiation of Clinical Development of TRAIL-R2 mAb for Treatment of Cancer by Human Genome Sciences, Inc
Level 5 Item Cambridge Antibody Technology and Amgen Restructure Existing Agreement
Level 5 Item Cambridge Antibody Technology Reports announcement from Abbott Laboratories regarding HUMIRA™ and ABT-874
Level 5 Item Cambridge Antibody Technology Reports the Development of ABthrax™by Human Genome Sciences, Inc
Level 5 Item Micromet, Enzon and Cambridge Antibody Technology Sign Cross-Licence Agreement in the Field of Single-Chain Antibodies and Phage Display
Level 5 Item Cambridge Antibody Technology Group plc Preliminary Statement of Results for the Year Ended 30 September 2003
Level 5 Item Cambridge Antibody Technology announces new Non-Executive Director
Level 5 Item Cambridge Antibody Technology Group plc Announces Result of EGM
Level 5 Item Cambridge Antibody Technology Group plc (“CAT”) and Oxford Glycosciences plc (“OGS”) - Proposed Merger of CAT and OGS - Merger
Level 5 Item Cambridge Antibody Technology Announces Management Appointments
Level 5 Item Cambridge Antibody Technology Group Plc Announces Result of EGM
Level 5 Item Cambridge Antibody Technology and Xerion Pharmaceuticals Expand Alliance into Antibody Drug Development
Level 5 Item Cambridge Antibody Technology and Genzyme Corporation Strengthen Collaboration
Level 5 Item Cambridge Antibody Technology and Dyax Corp. Further Expand Licensing Agreement
Level 5 Item Cambridge Antibody Technology Announces Product Licence Agreement With Micromet AG
Level 5 Item Cambridge Antibody Technology announces management promotions
Level 5 Item Cambridge Antibody Technology Group plc Announces First Quarter Results
Level 5 Item Cambridge Antibody Technology Reports Granting of Positive Opinion for HUMIRA™ by European Medicines Evaluation Agency
Level 5 Item Cambridge Antibody Technology - HUMIRA™ Royalties
Level 5 Item Cambridge Antibody Technology Reports Completion of Enrolment in European Phase II/III Trial of CAT-152™ in Glaucoma Surgery
Level 5 Item Cambridge Antibody Technology Group - Interim Results for the Six Months Ended 31 March 2003
Level 5 Item Cambridge Antibody Technology reports HUMIRA approval
Level 5 Item Cambridge Antibody Technology and Dyax Expand Licensing Agreement
Level 5 Item Cambridge Antibody Technology Group plc Reports Outcome of Annual General Meeting
Level 4 Item 2002
Level 5 Item Expiry of Bid by Cambridge Antibody Technology Group plc for Drug Royalty Corporation Inc.
Level 5 Item Cambridge Antibody Technology Group plc 2002 Annual General Meeting Statement
Level 5 Item Cambridge Antibody Technology and Human Genome Sciences Commit to Exclusive Development of Antibody to Trail Receptor-2
Level 5 Item Cambridge Antibody Technology Further Extends Offer for Drug Royalty Corporation to 26 April 2002
Level 5 Item Cambridge Antibody Technology and Xerion Pharmaceuticals Enter Research Collaboration
Level 5 Item Cambridge Antibody Technology and Xoma Cross-license Antibody Technologies
Level 5 Item Cambridge Antibody Technology Extends Offer for Drug Royalty Corporation to 27 March 2002
Level 5 Item Cambridge Antibody Technology Announces the Share Exchange Ratio for its Offer to Acquire All of the Outstanding Common Shares of Drug Royalty Corporation and that it Will Pay the Top Up Amount and the Additional Top Up Amount Entirely in Cambridge Antibo
Level 5 Item Cambridge Antibody Technology ("CAT") and Drug Royalty Corporation ("DRC") Announce C$126 Million (£55 Million) Share for Share Offer to be Made by CAT for DRC
Level 5 Item Cambridge Antibody Technology Announces Progress in Human Antibodies Alliance with Immunex Corporation
Level 5 Item Cambridge Antibody Technology Announces the Mailing of the Notice of Extension and Variation of its Offer for Drug Royalty Corporation
Level 5 Item Cambridge Antibody Technology Group plc Terminates Royalty Agreement with Drug Royalty Corporation Inc.
Level 5 Item Cambridge Antibody Technology and MorphoSys Settle Patent Disputes
Level 5 Item Cambridge Antibody Technology Announces Positive 12 Month Phase II Results for CAT-152
Level 5 Item Cambridge Antibody Technology Broadens Relationship with Merck & Co., Inc.
Level 5 Item Cambridge Antibody Technology Partners with Chugai to Develop Novel Human Monoclonal Antibodies
Level 5 Item